In Vitro Carbon Ion Beam and Gemcitabine Chemoradiation in a Mucoepidermoid Carcinoma Cell Line
In Vivo · 2023
DOI: 10.21873/invivo.13291 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2023. Verfasst von Thomas Schneider und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Mucoepidermoid, Heavy Ion Radiotherapy. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.
- Clinical Cooperation Unit E055, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.
- National Center for Radiation Research in Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany.
- DKTK Site Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zitieren
APA
Schneider, T., Zwicker, F., Huber, P. E., Debus, J., & Hauswald, H. (2023). In Vitro Carbon Ion Beam and Gemcitabine Chemoradiation in a Mucoepidermoid Carcinoma Cell Line. In Vivo. https://doi.org/10.21873/invivo.13291
Vancouver
Schneider T, Zwicker F, Huber PE, Debus J, Hauswald H. In Vitro Carbon Ion Beam and Gemcitabine Chemoradiation in a Mucoepidermoid Carcinoma Cell Line. In Vivo. 2023. doi:10.21873/invivo.13291
BibTeX
@article{Schneider2023,
author = {Schneider, Thomas and Zwicker, Felix and Huber, Peter Ernst and Debus, Jürgen and Hauswald, Henrik},
title = {In Vitro Carbon Ion Beam and Gemcitabine Chemoradiation in a Mucoepidermoid Carcinoma Cell Line},
journal = {In Vivo},
year = {2023},
doi = {10.21873/invivo.13291}
}
EUVIMED